Polycomb-like Protein 3 Induces Proliferation and Drug Resistance in Multiple Myeloma and Is Regulated by miRNA-15a.

3' Untranslated Regions Animals Cell Line, Tumor Cell Proliferation DNA-Binding Proteins / genetics Drug Resistance, Neoplasm Enhancer of Zeste Homolog 2 Protein / metabolism Gene Expression Regulation, Neoplastic Humans Mice MicroRNAs / genetics Multiple Myeloma / genetics Neoplasm Transplantation Phosphorylation Prognosis Signal Transduction Survival Analysis Transcription Factors / genetics Up-Regulation

Journal

Molecular cancer research : MCR
ISSN: 1557-3125
Titre abrégé: Mol Cancer Res
Pays: United States
ID NLM: 101150042

Informations de publication

Date de publication:
07 2020
Historique:
received: 19 08 2019
revised: 27 11 2019
accepted: 16 04 2020
pubmed: 22 4 2020
medline: 3 7 2021
entrez: 22 4 2020
Statut: ppublish

Résumé

Multiple myeloma remains incurable due to the persistence of a minor population of multiple myeloma cells that exhibit drug resistance, which leads to relapsed and/or refractory multiple myeloma. Elucidating the mechanism underlying drug resistance and developing an effective treatment are critical for clinical management of multiple myeloma. Here we showed that promoting expression of the gene for polycomb-like protein 3 (PHF19) induced multiple myeloma cell growth and multidrug resistance

Identifiants

DOI: 10.1158/1541-7786.MCR-19-0852 PMID: 32312841
pubmed: 32312841
pii: 1541-7786.MCR-19-0852
doi: 10.1158/1541-7786.MCR-19-0852
doi:

Substances chimiques

3' Untranslated Regions 0
DNA-Binding Proteins 0
MIRN15 microRNA, human 0
MicroRNAs 0
PHF19 protein, human 0
Transcription Factors 0
EZH2 protein, human EC 2.1.1.43
Enhancer of Zeste Homolog 2 Protein EC 2.1.1.43

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1063-1073

Informations de copyright

©2020 American Association for Cancer Research.

Auteurs

Tengteng Yu (T)

State Key Laboratory of Experimental Hematology, National Clinical Research Center for Hematological Disorders, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.
Jerome Lipper Multiple Myeloma Center, LeBow Institute for Myeloma Therapeutics, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.

Chenxing Du (C)

State Key Laboratory of Experimental Hematology, National Clinical Research Center for Hematological Disorders, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.

Xiaoke Ma (X)

School of Computer Science and Technology, Xidian University, Xi'an, China.
ORCID: 0000-0002-5604-7137

Weiwei Sui (W)

State Key Laboratory of Experimental Hematology, National Clinical Research Center for Hematological Disorders, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.

Zhen Yu (Z)

State Key Laboratory of Experimental Hematology, National Clinical Research Center for Hematological Disorders, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.

Lanting Liu (L)

State Key Laboratory of Experimental Hematology, National Clinical Research Center for Hematological Disorders, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.

Lei Zhao (L)

Department of Biophysics and Molecular Physiology, The University of Iowa, Roy J and Lucille A. Carver College of Medicine, Iowa City, Iowa.

Zhongqing Li (Z)

State Key Laboratory of Experimental Hematology, National Clinical Research Center for Hematological Disorders, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.
ORCID: 0000-0002-0417-2147

Jie Xu (J)

State Key Laboratory of Experimental Hematology, National Clinical Research Center for Hematological Disorders, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.

Xiaojing Wei (X)

State Key Laboratory of Experimental Hematology, National Clinical Research Center for Hematological Disorders, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.

Wen Zhou (W)

Key Laboratory of Carcinogenesis, Ministry of Health, Key Laboratory of Carcinogenesis and Cancer Invasion, Ministry of Education, Xiangya Hospital; Cancer Research Institute, School of Basic Medicine, Central South University, Changsha, Hunan, China.
ORCID: 0000-0003-4085-7714

Shuhui Deng (S)

State Key Laboratory of Experimental Hematology, National Clinical Research Center for Hematological Disorders, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.

Dehui Zou (D)

State Key Laboratory of Experimental Hematology, National Clinical Research Center for Hematological Disorders, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.

Gang An (G)

State Key Laboratory of Experimental Hematology, National Clinical Research Center for Hematological Disorders, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.

Yu-Tzu Tai (YT)

Jerome Lipper Multiple Myeloma Center, LeBow Institute for Myeloma Therapeutics, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.
ORCID: 0000-0001-6199-3569

Guido Tricot (G)

Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, Arkansas.

Kenneth C Anderson (KC)

Jerome Lipper Multiple Myeloma Center, LeBow Institute for Myeloma Therapeutics, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts.

Lugui Qiu (L)

State Key Laboratory of Experimental Hematology, National Clinical Research Center for Hematological Disorders, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.

Fenghuang Zhan (F)

Myeloma Center, University of Arkansas for Medical Sciences, Little Rock, Arkansas.

Mu Hao (M)

State Key Laboratory of Experimental Hematology, National Clinical Research Center for Hematological Disorders, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China. haomu@ihcams.ac.cn.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Phénomènes génétiques › Structures génétiques › Génome › Composants de génome › Gènes › Composants de gène › Régions non traduites › Régions 3' non traduites › Polycomb-like Protein 3 Induces Proliferation...
questionsmedicales.fr › Eucaryotes › Animaux › Polycomb-like Protein 3 Induces Proliferation...
questionsmedicales.fr › Cellules › Cellules cultivées › Cellules cancéreuses en culture › Lignée cellulaire tumorale › Polycomb-like Protein 3 Induces Proliferation...
questionsmedicales.fr › Phénomènes physiologiques › Croissance et développement › Croissance › Processus de croissance cellulaire › Prolifération cellulaire › Polycomb-like Protein 3 Induces Proliferation...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines de liaison à l'ADN › Polycomb-like Protein 3 Induces Proliferation...
questionsmedicales.fr › Phénomènes physiologiques › Phénomènes pharmacologiques et toxicologiques › Phénomènes pharmacologiques › Résistance aux substances › Résistance aux médicaments antinéoplasiques › Polycomb-like Protein 3 Induces Proliferation...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Facteurs de transcription › Protéines de répression › Protéines du groupe Polycomb › Complexe répresseur Polycomb-2 › Protéine-2 homologue de l'activateur de Zeste › Polycomb-like Protein 3 Induces Proliferation...
questionsmedicales.fr › Phénomènes génétiques › Régulation de l'expression des gènes › Régulation de l'expression des gènes tumoraux › Polycomb-like Protein 3 Induces Proliferation...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Polycomb-like Protein 3 Induces Proliferation...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Rodentia › Muridae › Murinae › Souris › Polycomb-like Protein 3 Induces Proliferation...
questionsmedicales.fr › Acides nucléiques, nucléotides et nucléosides › Acides nucléiques › ARN › ARN non traduit › Petit ARN non traduit › microARN › Polycomb-like Protein 3 Induces Proliferation...
questionsmedicales.fr › Maladies du système immunitaire › Syndromes immunoprolifératifs › Paraprotéinémies › Myélome multiple › Polycomb-like Protein 3 Induces Proliferation...
questionsmedicales.fr › Techniques d'investigation › Transplantation tumorale › Polycomb-like Protein 3 Induces Proliferation...
questionsmedicales.fr › Métabolisme › Phosphorylation › Polycomb-like Protein 3 Induces Proliferation...
questionsmedicales.fr › Diagnostic › Pronostic › Polycomb-like Protein 3 Induces Proliferation...
questionsmedicales.fr › Phénomènes physiologiques cellulaires › Transduction du signal › Polycomb-like Protein 3 Induces Proliferation...
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Statistiques comme sujet › Analyse de survie › Polycomb-like Protein 3 Induces Proliferation...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Facteurs de transcription › Polycomb-like Protein 3 Induces Proliferation...
questionsmedicales.fr › Phénomènes physiologiques › Phénomènes pharmacologiques et toxicologiques › Phénomènes pharmacologiques › Régulation positive › Polycomb-like Protein 3 Induces Proliferation...